title: Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
abstract: Dendritic cells (DC) are potent professional antigen-presenting cells that can activate naive T lymphocytes and initiate cellular immune responses. As adjuvants, DC may be useful in enhancing the immunogenicity of tumor antigens and mediating tumor regression. Endogenous expression of antigen by DC offers the potential advantage of allowing prolonged constitutive presentation of endogenously processed epitopes and exploitation of multiple restriction elements for the presentation of the same antigen. In this report, we show that human DC are (a) capable of infection by recombinant poxviruses encoding melanoma-associated antigen (MAA) genes and (b) capable of efficiently processing and presenting these MAA to cytotoxic T cells. In 6/6 HLA A*0201-expressing melanoma patients tested, the virally driven expression of MART-1/Melan A MAA by DC was sufficient to generate CD8+ T lymphocytes that could recognize naturally processed epitopes on tumor cells. In most cases, specific anti-MART-1 reactivity could be detected after a single stimulation. Analysis of epitope dominance revealed that the amino acid sequence recognized by these cytotoxic T lymphocytes (CTL) corresponded to the MART-1(27-35) residues previously shown to be most commonly recognized by cytotoxic T lymphocytes expanded from metastatic melanoma lesions. These data show that the virally driven expression of MAA by DC can be exploited for the efficient induction of clinically relevant cytotoxic T-cell responses. This has clinical implications for active immunization therapy, and currently vaccine trials have been proposed for patients with metastatic melanoma.
authors.affiliation: Department of Surgery, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: Kim
authors.forename: T
authors.initials: T
authors.lastname: Prevette
authors.forename: J
authors.initials: J
authors.lastname: Cormier
authors.forename: W
authors.initials: W
authors.lastname: Overwijk
authors.forename: M
authors.initials: M
authors.lastname: Roden
authors.forename: N P
authors.initials: NP
authors.lastname: Restifo
authors.forename: S A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: F M
authors.initials: FM
authors.lastname: Marincola
mesh_terms: D017951:Antigen Presentation; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D003713:Dendritic Cells / Q000276:immunology* / Q000821:virology; D015395:Histocompatibility Antigens Class I / Q000276:immunology; D006801:Humans; D016056:Immunodominant Epitopes; D058965:MART-1 Antigen; D008545:Melanoma / Q000628:therapy; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D011212:Poxviridae / Q000235:genetics*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*
chemical_list: D000951:Antigens, Neoplasm; D015395:Histocompatibility Antigens Class I; D016056:Immunodominant Epitopes; D058965:MART-1 Antigen; C548667:MLANA protein, human; D009363:Neoplasm Proteins